Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 2, 2016, Pages 282-287

  Gisondi, P ^a   Barba, E ^a   Girolomoni, G ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FATTY LIVER; FEMALE; HUMAN; HYPERTENSION; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RISK ASSESSMENT; SCORING SYSTEM; SEX; COMPLICATION; ITALY; NON-ALCOHOLIC FATTY LIVER DISEASE; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR;

CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROGNOSIS; PSORIASIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84956493530     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13456     Document Type: Article

References (40)

1. Griffiths CE, Barker JN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
2. Sommer DM, Jenisch S, Suchan M, et al,. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-328.
3. Gisondi P, Tessari G, Conti A, et al,. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
4. Boehncke S, Thaci D, Beschmann H, et al,. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157: 1249-1251.
5. Masarone M, Federico A, Abenavoli L, et al,. Non-alcoholic Fatty liver: epidemiology and natural history. Rev Recent Clin Trials 2014; 9: 126-133.
6. Roberts KK, Cochet AE, Lamb PB, et al,. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther 2015; 41: 293-300.
7. Miele L, Vallone S, Cefalo C, et al,. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-786.
8. van der Voort EA, Koehler EM, Dowlatshahi EA, et al,. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study. J Am Acad Dermatol 2014; 70: 517-524.
9. Gisondi P, Targher G, Zoppini G, et al,. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-764.
10. Adams LA, Angulo P, Lindor KD,. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899-905.
11. Marchesini G, Marzocchi R, Agostini F, et al,. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16: 421-427.
12. Kotronen A, Yki-Jarvinen H,. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thrombosis Vasc Biol 2008; 28: 27-38.
13. Angulo P, Hui JM, Marchesini G, et al,. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
14. Taylor W, Gladman D, Helliwell P, et al,. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673.
15. Targher G, Bertolini L, Padovani R, et al,. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218.
16. Charlton M,. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004; 2: 1048-1058.
17. Kleiner DE, Brunt EM, Van Natta M, et al,. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
18. Castera L, Vilgrain V, Angulo P,. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10: 666-675.
19. Leite NC, Salles GF, Araujo AL, et al,. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29: 113-119.
20. Prashanth M, Ganesh HK, Vima MV, et al,. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India 2009; 57: 205-210.
21. Xu H, Uysal KT, Becherer JD, et al,. Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity. Diabetes 2002; 51: 1876-1883.
22. Feldstein AE, Werneburg NW, Canbay A, et al,. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004; 40: 185-194.
23. Crespo J, Cayon A, Fernandez-Gil P, et al,. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-1163.
24. Carter-Kent C, Zein NN, Feldstein AE,. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 2008; 103: 1036-1042.
25. Campanati A, Ganzetti G, Di Sario A, et al,. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol 2013; 48: 839-846.
26. Lonardo A, Sookoian S, Chonchol M, et al,. Cardiovascular and systemic risk in nonalcoholic fatty liver disease-atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 2013; 19: 5177-5192.
27. Sookoian S, Pirola CJ,. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008; 49: 600-607.
28. Bhatia LS, Curzen NP, Calder PC, et al,. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012; 33: 1190-1200.
29. Targher G, Day CP, Bonora E,. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350.
30. Ekstedt M, Franzen LE, Mathiesen UL, et al,. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
31. Stepanova M, Younossi ZM,. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012; 10: 646-650.
32. Rosenberg P, Urwitz H, Johannesson A, et al,. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46: 1111-1118.
33. Chalasani N, Younossi Z, Lavine JE, et al,. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-1609.
34. Casey SP, Kemp WW, McLean CA, et al,. A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease. Scand J Gastroenterol 2012; 47: 836-841.
35. Musso G, Gambino R, Cassader M, et al,. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649.
36. Harrison SA, Oliver D, Arnold HL, et al,. Development and validation of a simple NAFLD c linical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-1447.
37. Gawrieh S, Chalasani N,. NAFLD fibrosis score: is it ready for wider use in clinical practice and for clinical trials? Gastroenterology 2013; 145: 717-719.
38. Subasi CF, Aykut UE, Yilmaz Y,. Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2015; 27: 137-141.
39. Fedchuk L, Nascimbeni F, Pais R, et al,. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014; 40: 1209-1222.
40. Petta S, Vanni E, Bugianesi E, et al,. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2015; 35: 1566-1573.